HS Research Update (25 May 2026): What's New on PubMed? Canonical URL: https://acneinversa.life/en/blog/hs-research-update-2026-05-25/ Markdown URL: https://acneinversa.life/en/blog/hs-research-update-2026-05-25.md Plain text URL: https://acneinversa.life/en/blog/hs-research-update-2026-05-25.txt Language: en Category: Research Published: 2026-05-25 Last updated: 2026-05-25 Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert) Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, Hidradenitis suppurativa, Acne inversa, Research update, Biologics, Comorbidities, JAK inhibitor, Quality of life, Surgery, Wound care A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical recommendations. Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions. Article Publication overview This update covers 8 PubMed publications with abstracts from the period 17 May 2026 to 25 May 2026. The most common topics are biologics, wound care, JAK inhibitors, surgery, quality of life, and comorbidities. - Compared with the previous update (/en/blog/hs-research-update-2026-05-20/): not automatically assessed. - During this period, no high-tier hits in the sense of guidelines/NEJM/Lancet with abstracts were found. - This is a research overview, not a guideline update and not a medical recommendation. Key highlights The most useful signal in this round is not a single treatment instruction. It is what researchers are currently examining more closely: wound healing after procedures, possible new anti-inflammatory approaches, quality of care, and comorbidities. - Wound care after deroofing: A randomised split-body study investigates whether a bioelectric wound dressing after HS deroofing can change the wound environment and microbiome. What's new here is the perspective: postoperative wound care is being studied as an active component of the treatment outcome and not just as routine aftercare. (PMID 42164272 (https://pubmed.ncbi.nlm.nih.gov/42164272/)) - IL-17 therapy and side-effect management: A practice-oriented perspective addresses mucocutaneous candidiasis during bimekizumab therapy in HS. The new angle is not yet another efficacy claim, but rather how prevention and early management of a known side effect of the IL-17 pathway could influence tolerability and treatment adherence. (PMID 42165325 (https://pubmed.ncbi.nlm.nih.gov/42165325/)) - HS competence centres: A Delphi consensus publication defines criteria for specialised HS centres. This is less about a single medication or procedure and more about quality of care: which expertise, coordination, and services should be available when HS care becomes complex? (PMID 42176118 (https://pubmed.ncbi.nlm.nih.gov/42176118/)) - A possible new anti-inflammatory mechanism of action: The review article on RGRN-305 summarises early work on an Hsp90 inhibitor in inflammatory skin diseases, including HS. What's new is the therapeutic hypothesis that Hsp90 inhibition could modulate inflammatory signalling pathways; larger studies are still required. (PMID 42176147 (https://pubmed.ncbi.nlm.nih.gov/42176147/)) - Biology of comorbidities: A multi-omics study examines shared mechanisms between depression and inflammatory dermatoses. For HS, the useful signal is that mental health comorbidity is being investigated together with inflammatory biology and not just as a secondary quality-of-life topic. (PMID 42164085 (https://pubmed.ncbi.nlm.nih.gov/42164085/)) Featured publication The featured paper is the randomised split-body study of a bioelectric wound dressing after HS deroofing in JID Innovations: Skin Science from Molecules to Population Health (PMID 42164272 (https://pubmed.ncbi.nlm.nih.gov/42164272/)). According to the abstract, patients with bilateral axillary HS underwent deroofing, with one side assigned to the bioelectric wound dressing and the other to standard wound care. This makes the study more than a dressing comparison: it investigates whether the postoperative wound environment, including the microbiome associated with the tunnels, can be changed in measurable ways. Why it stands out: HS surgery is often discussed in terms of removing tunnels or diseased tissue, but the weeks after the procedure are enormously important for patients. Healing time, pain, recurrence, odour, drainage, and the effort of dressing changes significantly affect daily life. This is still a small study with short follow-up, so it should be read as a signal worth testing rather than as practice-changing evidence. Its value lies in turning postoperative wound care into a research question with measurable endpoints. What this could mean for patients (cautiously, without recommendation) If you live with HS, research updates can help you understand what is being studied — for example, which endpoints (pain, quality of life) researchers are measuring or which comorbidities are increasingly part of the conversation. But even when a study sounds promising, it usually does not tell you what is right for you personally. Use new findings more as questions for your next appointment (/en/blog/15-questions-to-ask-your-dermatologist/) (e.g. "What are realistic goals for me?" or "Which associated conditions should we keep an eye on?") rather than as instructions for action. What we don't know / limitations - This update includes only PubMed entries with an abstract (without an abstract, a reliable summary is only possible to a limited extent). - The studies differ considerably (design, populations, endpoints). - This update provides no treatment recommendation and cannot assess individual risks. Important: decisions belong in a conversation with professionals This article is an editorial overview and not medically peer-reviewed. If anything here concerns or interests you, use it as a starting point for a conversation at your next appointment. Decisions should always be made together with qualified healthcare professionals. Sources & original works Each point below links to an original source (PubMed link, plus DOI/PMCID where applicable). FAQ Why are weekly HS research updates useful? They help you see which questions researchers are currently investigating — for example, pain, quality of life, or comorbidities — so you can bring informed questions to your next appointment. They are not a substitute for medical advice. Will the studies summarised here change clinical practice? Usually not on their own. Most abstracts describe early findings, small studies, or single-centre experiences. Changes in practice typically require larger trials, replication, and assessment by guideline committees. What does 'no abstract available' mean for this update? PubMed entries without an abstract cannot be safely summarised in plain language. To avoid misinterpretation, this update only includes entries for which an abstract is available. How should I use this information with my dermatologist? Bring concrete questions, for example about realistic treatment goals, wound care after surgery, or comorbidities that should be monitored. Decisions about your care should always be made together with qualified healthcare professionals. References 1. A bioelectric dressing improves postderoofing outcomes in hidradenitis suppurativa by microbiome modulation: A split-body, randomized clinical trial. - JID innovations : skin science from molecules to population health, 2026 — PMID 42164272 · DOI 10.1016/j.xjidi.2026.100461 · PMCID PMC13185992 - https://pubmed.ncbi.nlm.nih.gov/42164272/ 2. RGRN-305, a novel Hsp90 inhibitor: a promising therapeutic option for inflammatory dermatologic diseases. - Inflammopharmacology, 2026 — PMID 42176147 · DOI 10.1007/s10787-026-02265-8 - https://pubmed.ncbi.nlm.nih.gov/42176147/ 3. Criteria for Hidradenitis Suppurativa Competence Centers. - Dermatology and therapy, 2026 — PMID 42176118 · DOI 10.1007/s13555-026-01783-1 - https://pubmed.ncbi.nlm.nih.gov/42176118/ 4. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. - Dermatology and therapy, 2026 — PMID 42171987 · DOI 10.1007/s13555-026-01724-y - https://pubmed.ncbi.nlm.nih.gov/42171987/ 5. Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective. - International journal of dermatology, 2026 — PMID 42165325 · DOI 10.1111/ijd.70491 - https://pubmed.ncbi.nlm.nih.gov/42165325/ 6. European Expert Consensus on Essential Variables for Teledermatological Assessment of Skin Tumours. - Acta dermato-venereologica, 2026 — PMID 42163824 · DOI 10.2340/actadv.v106.adv-2026-0512 · PMCID PMC13191222 - https://pubmed.ncbi.nlm.nih.gov/42163824/ 7. A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings. - The Australasian journal of dermatology, 2026 — PMID 42163520 · DOI 10.1111/ajd.70141 - https://pubmed.ncbi.nlm.nih.gov/42163520/ 8. A Multi-Omics Study of Comorbid Mechanisms Between Depression and Inflammatory Dermatoses Identifies FADS1 and TMEM258 as Therapeutic Targets. - Clinical, cosmetic and investigational dermatology, 2026 — PMID 42164085 · DOI 10.2147/CCID.S607365 · PMCID PMC13186223 - https://pubmed.ncbi.nlm.nih.gov/42164085/